Traws Pharma
TRAW
13 hedge funds and large institutions have $11.1M invested in Traws Pharma in 2014 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 7 closing their positions.
19% less funds holding
Funds holding: 16 → 13 (-3)
41% less capital invested
Capital invested by funds: $18.7M → $11.1M (-$7.65M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
90% less call options, than puts
Call options by funds: $6K | Put options by funds: $62K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$885K |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$590K |
| 3 |
Goldman Sachs
New York
|
+$295K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$295K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$295K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.66M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$1.22M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$885K |
| 4 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$697K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$590K |
TRAW Hedge Fund Activity: Q2 2014 in Review
13 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q2 2014, worth a combined $11.1M — down 41% from $18.7M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TRAW and 4 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $885K. The largest seller was Fidelity Investments, cutting an estimated $2.66M.
- 13 institutional investors held Traws Pharma (TRAW) as of Q2 2014, down from 16 in Q1 2014.
- Funds reported $11.1M of Traws Pharma stock for Q2 2014, down 41% quarter-over-quarter.
- 4 funds opened new Traws Pharma positions in Q2 2014 and 7 closed out, a net change of -3 holders.
- The largest Traws Pharma buyer in Q2 2014 was Renaissance Technologies, an estimated $885K added.
- The largest Traws Pharma seller in Q2 2014 was Fidelity Investments, an estimated $2.66M sold.
Based on aggregated 13F filings for Q2 2014.